详情页

资源类型：

文章类型：

作者：

X. Wu[1] * ; J. Zhu[2] ; J. Wang[3] ; Z. Lin[4] ; B. Kong[5] ; R. Yin[6] ; W. Sun[7] ; Q. Zhou[8] ; S. Zhang[9] ; D. Wang[10] ; H. Shi[11] ; Y. Gao[12] ; Y. Huang[13] ; G. Li[14] ; X. Wang[15] ; Y. Cheng[16] ; G. Lou[17] ; L. Li[18] ; X. Mu[19] ; M. Li[20] ;

机构： [1]Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, China [2]Department of Gynecologic Oncology, Zhejiang Cancer Hospital, Hangzhou, China [3]Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China [4]Department of Gynecological Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China [5]Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Ji’nan, China [6]Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China [7]Department of Gynecologic Oncology, Anhui Provincial Cancer Hospital, The First Affiliated Hospital of USTC, Hefei, China [8]Department of Gynecologic Oncology, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, Chongqing, China [9]Department of Obstetrics and Gynecology, The First Hospital of Jilin University, Changchun, China [10]Department of Gynecology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China [11]Department of Obstetrics and Gynecology, First Affiliated Hospital, Dalian Medical University, Dalian, China [12]Department of Gynecological Oncology, Peking University School of Oncology, Beijing Cancer Hospital, Beijing Institute for Cancer Research, Beijing, China [13]Department of Gynecological Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China [14]Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China [15]Department of Oncology and Hematology, The Second Hospital of Jilin University, Changchun, China [16]Department of Oncology, Jilin Cancer Hospital, Changchun, Jilin, China [17]Department of Gynecology, Harbin Medical University Cancer Hospital, Harbin, China [18]Biostatistics, BeiGene (Beijing) Co., Ltd., Beijing, China [19]Clinical Development, BeiGene (Shanghai) Co., Ltd., Shanghai, China [20]Clinical Development, BeiGene (Beijing) Co., Ltd., Beijing, China

出处：

DOI：

ISSN：

基金：

语种：

被引次数：

WOS：

中科院分区：

出版当年[2020]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

JCR分区：

出版当年[2020]版：

Q1 ONCOLOGY

最新[2024]版：

Q1 ONCOLOGY

第一作者：

第一作者机构： [1]Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

Phase II study of pamiparib in Chinese patients (pts) with advanced ovarian cancer (aOC)

文献详情